FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2409944350> ?p ?o ?g. }

• W2409944350 endingPage "9" @default.
• W2409944350 startingPage "115" @default.
• W2409944350 abstract "New antimetabolic drugs, purine-analogous, have been introduced in the treatment of advanced or refractory cases of chronic lymphocytic leukaemia (CLL), fludarabine (FLU) being one of such drugs. The results attained with FLU in 6 cases of refractory CLL are reported.The efficacy and toxicity of FLU was evaluated in 6 patients (median age 63 years) between March 1993 and March 1994. Five patients were in stage III-IV and one in stage II of the Rai's system, and they were refractory to the usual treatment. The dosis used here was 30 mg/sq m/day, for 5 days every 4 weeks, up to a total of 6 therapeutic courses. The response was assessed after 3 and 6 courses. Anti-infectious prophylaxis was made with co-trimoxazole, monthly benzathine penicillin G and isoniazid in Mantoux-positive patients. The response criteria were those given by the NIC Working Group for CLL.The patients received 2 to 6 courses. None of them attained complete remission: 1 had nodular remission, 2 had partial remission, 2 responded partially although not reaching criteria for partial remission (1 died of pancytopenia), and 1 had disease progression and died after the second course. Fast and important reduction of the lymphocyte count as well as the CD4 lymphocytes was present in all cases. Bone-marrow infiltration decreased strikingly in 2 cases and the platelet count improved in 3 cases and worsened in 2 others. The following toxicity was recorded: 2 patients had nausea, 5 had neutropenia (below 500 x 10(9)/L in 3 instances) and 4 had thrombocytopenia (lower than 40 x 10(9)/L in one case). In 26 therapeutic courses there were 10 febrile episodes (1 for pneumonia, 1 for gastroenteritis and 8 without any septic foci); 1 patient developed pulmonary tuberculosis after completing the treatment and one patient died of posttransfusion graft versus host disease after splenectomy once she had completes six courses.This experience confirms the efficacy of FLU in the treatment of refractory B-CLL patients and is in agreement with previous reports as no response is initiated after the 3rd course. The lymphocyte count decreases quickly and strikingly. Depletion of CD4 lymphocytes along with neutropenia and hypogammaglobulinaemia make these patients highly sensitive to all types of infection, chiefly by opportunistic germs, so adequate anti-infectious prophylaxis is of great importance. The two patients with pre-treatment haemoglobin and platelet values lower than 10 g/dL and 40 x 10(9)/L, respectively, were the only ones in need of transfusion. No cumulative myelosuppression was appreciated." @default.
• W2409944350 created "2016-06-24" @default.
• W2409944350 creator A5024183084 @default.
• W2409944350 creator A5026068036 @default.
• W2409944350 creator A5041478489 @default.
• W2409944350 creator A5045735997 @default.
• W2409944350 creator A5056058278 @default.
• W2409944350 creator A5057777126 @default.
• W2409944350 creator A5071693986 @default.
• W2409944350 creator A5086408321 @default.
• W2409944350 date "1995-04-01" @default.
• W2409944350 modified "2023-10-17" @default.
• W2409944350 title "[Treatment with fludarabine of chronic refractory lymphoid leukemia]." @default.
• W2409944350 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7784940" @default.
• W2409944350 hasPublicationYear "1995" @default.
• W2409944350 type Work @default.
• W2409944350 sameAs 2409944350 @default.
• W2409944350 citedByCount "3" @default.
• W2409944350 countsByYear W24099443502012 @default.
• W2409944350 crossrefType "journal-article" @default.
• W2409944350 hasAuthorship W2409944350A5024183084 @default.
• W2409944350 hasAuthorship W2409944350A5026068036 @default.
• W2409944350 hasAuthorship W2409944350A5041478489 @default.
• W2409944350 hasAuthorship W2409944350A5045735997 @default.
• W2409944350 hasAuthorship W2409944350A5056058278 @default.
• W2409944350 hasAuthorship W2409944350A5057777126 @default.
• W2409944350 hasAuthorship W2409944350A5071693986 @default.
• W2409944350 hasAuthorship W2409944350A5086408321 @default.
• W2409944350 hasConcept C121332964 @default.
• W2409944350 hasConcept C126322002 @default.
• W2409944350 hasConcept C141071460 @default.
• W2409944350 hasConcept C142424586 @default.
• W2409944350 hasConcept C146357865 @default.
• W2409944350 hasConcept C151730666 @default.
• W2409944350 hasConcept C2776694085 @default.
• W2409944350 hasConcept C2776755627 @default.
• W2409944350 hasConcept C2777063308 @default.
• W2409944350 hasConcept C2777866208 @default.
• W2409944350 hasConcept C2777938653 @default.
• W2409944350 hasConcept C2778461978 @default.
• W2409944350 hasConcept C2779263901 @default.
• W2409944350 hasConcept C2779338263 @default.
• W2409944350 hasConcept C2779382419 @default.
• W2409944350 hasConcept C2780007613 @default.
• W2409944350 hasConcept C2780580376 @default.
• W2409944350 hasConcept C2780653079 @default.
• W2409944350 hasConcept C29730261 @default.
• W2409944350 hasConcept C71924100 @default.
• W2409944350 hasConcept C86803240 @default.
• W2409944350 hasConcept C87355193 @default.
• W2409944350 hasConcept C90924648 @default.
• W2409944350 hasConceptScore W2409944350C121332964 @default.
• W2409944350 hasConceptScore W2409944350C126322002 @default.
• W2409944350 hasConceptScore W2409944350C141071460 @default.
• W2409944350 hasConceptScore W2409944350C142424586 @default.
• W2409944350 hasConceptScore W2409944350C146357865 @default.
• W2409944350 hasConceptScore W2409944350C151730666 @default.
• W2409944350 hasConceptScore W2409944350C2776694085 @default.
• W2409944350 hasConceptScore W2409944350C2776755627 @default.
• W2409944350 hasConceptScore W2409944350C2777063308 @default.
• W2409944350 hasConceptScore W2409944350C2777866208 @default.
• W2409944350 hasConceptScore W2409944350C2777938653 @default.
• W2409944350 hasConceptScore W2409944350C2778461978 @default.
• W2409944350 hasConceptScore W2409944350C2779263901 @default.
• W2409944350 hasConceptScore W2409944350C2779338263 @default.
• W2409944350 hasConceptScore W2409944350C2779382419 @default.
• W2409944350 hasConceptScore W2409944350C2780007613 @default.
• W2409944350 hasConceptScore W2409944350C2780580376 @default.
• W2409944350 hasConceptScore W2409944350C2780653079 @default.
• W2409944350 hasConceptScore W2409944350C29730261 @default.
• W2409944350 hasConceptScore W2409944350C71924100 @default.
• W2409944350 hasConceptScore W2409944350C86803240 @default.
• W2409944350 hasConceptScore W2409944350C87355193 @default.
• W2409944350 hasConceptScore W2409944350C90924648 @default.
• W2409944350 hasIssue "2" @default.
• W2409944350 hasLocation W24099443501 @default.
• W2409944350 hasOpenAccess W2409944350 @default.
• W2409944350 hasPrimaryLocation W24099443501 @default.
• W2409944350 hasRelatedWork W1520544020 @default.
• W2409944350 hasRelatedWork W1991579226 @default.
• W2409944350 hasRelatedWork W2029388382 @default.
• W2409944350 hasRelatedWork W2117174961 @default.
• W2409944350 hasRelatedWork W2350942433 @default.
• W2409944350 hasRelatedWork W2409944350 @default.
• W2409944350 hasRelatedWork W2533912613 @default.
• W2409944350 hasRelatedWork W2900648479 @default.
• W2409944350 hasRelatedWork W2981027710 @default.
• W2409944350 hasRelatedWork W2743050652 @default.
• W2409944350 hasVolume "40" @default.
• W2409944350 isParatext "false" @default.
• W2409944350 isRetracted "false" @default.
• W2409944350 magId "2409944350" @default.
• W2409944350 workType "article" @default.